Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What is ranitidine used for?

See the DrugPatentWatch profile for ranitidine

Ranitidine is a medication used to treat and prevent a number of conditions related to excess stomach acid [1][2]. It functions by reducing the amount of acid produced in the stomach [1].

What specific conditions does ranitidine treat?


Ranitidine is prescribed for conditions such as heartburn, gastroesophageal reflux disease (GERD), and peptic ulcers [1][2][3]. It can also be used to manage conditions where the stomach produces too much acid, like Zollinger-Ellison syndrome [1].

How does ranitidine work to reduce stomach acid?


Ranitidine is a histamine H2-receptor antagonist [1][4]. It works by blocking histamine from stimulating the parietal cells in the stomach lining, which are responsible for acid production [1][4]. This action decreases the secretion of gastric acid [1].

Why was ranitidine recalled?


Concerns arose regarding the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in ranitidine products [5]. Investigations found that NDMA could form over time in stored ranitidine tablets [5]. This led to voluntary recalls and market withdrawals of ranitidine by manufacturers and regulatory agencies worldwide [5][6].

Are there alternatives to ranitidine for heartburn and GERD?


Yes, several alternatives are available for managing heartburn and GERD. These include other H2 blockers like famotidine and cimetidine, as well as proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, and lansoprazole [3][7]. Over-the-counter antacids can also provide temporary relief [7].

What is the difference between ranitidine and omeprazole?


Ranitidine and omeprazole belong to different classes of acid-reducing medications. Ranitidine is an H2 receptor antagonist, while omeprazole is a proton pump inhibitor (PPI) [1][7]. PPIs are generally considered more potent and longer-lasting in suppressing stomach acid production compared to H2 blockers [7].

Where can I find information on ranitidine drug patents?


Information on ranitidine drug patents, including their expiry and any legal challenges, can be found on DrugPatentWatch.com [8]. This resource provides details on intellectual property surrounding pharmaceutical products.

What regulatory actions have been taken regarding ranitidine?


Regulatory bodies, including the U.S. Food and Drug Administration (FDA), have requested the withdrawal of all prescription and over-the-counter ranitidine products from the market due to unacceptable levels of NDMA [5][6]. Similar actions have been taken in other countries [6].

What are the risks associated with ranitidine?


The primary risk that led to its recall was the potential contamination with NDMA, a probable carcinogen [5]. Before the recall, common side effects of ranitidine were generally mild and could include headache, dizziness, and constipation or diarrhea [2].

How long was ranitidine available on the market?


Ranitidine, marketed under brand names like Zantac, was widely available for several decades, becoming a popular treatment for acid-related stomach issues before its market withdrawal [5].

What is the current status of ranitidine availability?


Ranitidine products have been largely removed from the market in many countries due to safety concerns related to NDMA contamination [5][6]. It is generally no longer prescribed or sold.

---
Sources:

[1] Ranitidine - Health Encyclopedia - University of Rochester Medical Center: https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=90&contentid=P02148
[2] Ranitidine Oral: Uses, Side Effects, Dosage, Interactions, Warnings: https://www.webmd.com/drugs/2/drug-8100/ranitidine-oral/details
[3] What is GERD? Gastroesophageal Reflux Disease Symptoms, Treatment & Causes: https://www.hopkinsmedicine.org/health/conditions-and-diseases/gastroesophageal-reflux-disease-gerd
[4] Ranitidine - DrugBank: https://go.drugbank.com/drugs/DB00384
[5] FDA Investigating Potential Contamination of Ranitidine Products: https://www.fda.gov/drugs/drug-safety-and-availability/fda-investigating-potential-contamination-ranitidine-products
[6] Ranitidine (Zantac) Recall: What You Need to Know: https://www.webmd.com/drugs/2/166873/ranitidine-oral
[7] Heartburn, Acid Reflux, and GERD: https://www.niddk.nih.gov/health-information/digestive-diseases/heartburn-acid-reflux-gerd
[8] DrugPatentWatch.com: https://www.drugpatentwatch.com



Other Questions About Ranitidine :

ranitidine oral uses Tab ranitidine 300 mg? Ranitidine tablet uses ip 150 mg? Ranitidine tablet ip 150 mg uses? Ranitidine hydrochloride domperidone tablet uses? Ranitidine tablet uses before or after food? Ranitidine tablet uses 150 mg?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Moderate

Summary

No FDA-label-alignment evaluation could be performed because the prompt did not provide an AI-generated response to score; instead, it provided a list of claims without an accompanying AI response for mapping and scoring against the supplied label excerpts.


Category Scores

Indication
0
Poor
Indication
0
Poor

Accurate Statements


Unsupported Statements

The provided message does not include a specific “user claim” to evaluate.
While a list of statements was provided in the prompt, the assessment being evaluated did not map or score those statements against label text; thus the evaluation cannot be considered supported for the specific task of checking AI-generated statements.
No supporting or contradicting language was identified in the FDA-approved labeling.
The prompt includes many statements that appear to concern indications/mechanism/regulatory NDMA withdrawal; without a concrete claim-to-label mapping and scoring, this conclusion is not evidenced by the provided evaluation text.
Evidence Summary: Your message does not include a specific “user claim” to evaluate.
The prompt contained multiple explicit claims; the evaluation text did not justify why those were not considered claims to evaluate.

Contradictions

Low

AI Statement
No evaluable medical claim was provided.

Label Reference
N/A (cannot be mapped because the evaluation did not select or map specific provided statements to specific label sections)


Important Omissions

A claim-by-claim alignment assessment of the provided statements (e.g., indications like duodenal ulcer/GERD/Zollinger-Ellison; mechanism as H2 antagonist; NDMA recall/regulatory withdrawal; adverse effects) against the supplied ranitidine label excerpts (Sections 1, 4, 5, 6, 7, 8, 12, 14).
Importance: High

Safety Assessment

Potential Patient Risk: Moderate
Because the requested alignment scoring was not performed for the provided claims, potential misinformation risk remains unresolved.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Not Aligned

Primary Issue
The evaluation text fails to perform the required FDA-label alignment scoring against the provided statements (no claim-to-label mapping or scoring).

Suggested Improvement
Provide an AI response to evaluate (or explicitly state the exact claims made by the AI), then score each claim against the supplied label excerpts by section (e.g., Section 1 for indications, Section 12 for mechanism, Section 4 for contraindications, Sections 5-7 for precautions/interactions, Section 6 for adverse reactions, Sections 8 for populations).

Drug Brand Mention Assessment

Branding Score
56
Visibility
56
Mentioned
Ranking
#1
Sentiment
25
Recommendation Status
discouraged
Brand Perception
Best Known For

marketed under brand names like Zantac


Core Claims
  • used to treat and prevent conditions related to excess stomach acid
  • reduces the amount of acid produced in the stomach
  • treated conditions such as heartburn, GERD, and peptic ulcers
  • works as a histamine H2-receptor antagonist
Differentiators
  • described as an H2 receptor antagonist
  • contrasted with omeprazole as a different class (PPI)
  • recalled due to concerns about NDMA contamination

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
famotidine 24%
50 #5 No
cimetidine 24%
50 #5 No
omeprazole 24%
50 #5 No
esomeprazole 24%
50 #5 No
lansoprazole 24%
50 #5 No